In the same line, HAVCR2 was overexpressed by 1.338-fold (95% CI 1.006–1.779) in MSI tumors compared to corresponding normal colon tissue, whereas there were non-significant changes in MSS tumors, perhaps indicating a potential beneficial effect of HAVCR2 inhibitor in MSI CRC only (see Figure 9). Here, HAVCR2 is linked to colorectal carcinoma.